AstraZeneca PLC (AZN)vsOmada Health, Inc. Common Stock (OMDA)
AZN
AstraZeneca PLC
$186.43
-0.22%
HEALTHCARE · Cap: $263.78B
OMDA
Omada Health, Inc. Common Stock
$15.09
-20.37%
HEALTHCARE · Cap: $1.15B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 19711% more annual revenue ($61.37B vs $309.76M). AZN leads profitability with a 17.0% profit margin vs 1.4%. AZN trades at a lower P/E of 25.4x. AZN earns a higher WallStSmart Score of 62/100 (C+).
AZN
Buy62
out of 100
Grade: C+
OMDA
Hold40
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+13.1%
Fair Value
$194.96
Current Price
$186.43
$8.53 discount
Intrinsic value data unavailable for OMDA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Revenue surging 43.1% year-over-year
Areas to Watch
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
1.4% margin — thin
Operating margin of 4.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.22 suggests the stock is reasonably priced for its growth.
Bull Case : OMDA
The strongest argument for OMDA centers on Revenue Growth. Revenue growth of 43.1% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Bear Case : OMDA
The primary concerns for OMDA are EPS Growth, Market Cap, Profit Margin. A P/E of 78.0x leaves little room for execution misses. Thin 1.4% margins leave little buffer for downturns.
Key Dynamics to Monitor
AZN profiles as a mature stock while OMDA is a hypergrowth play — different risk/reward profiles.
OMDA is growing revenue faster at 43.1% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (62/100 vs 40/100), backed by strong 17.0% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Omada Health, Inc. Common Stock
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Omada Health, Inc. provides a range of virtual care programs in the United States. The company is headquartered in San Francisco, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?